Erosion Matrix for Fumaric Acid Ester Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psoriasis treatments with fumaric acid esters, such as Fumaderm, suffer from high gastrointestinal side effects and short-term efficacy, leading to patient discontinuation and suboptimal treatment outcomes due to rapid release and degradation of the active substances in the gastrointestinal tract.
Innovation Solution
A pharmaceutical formulation using an erosion matrix tablet with fumaric acid esters and water-soluble rate-controlling agents, combined with an enteric coating, to achieve controlled and sustained release, reducing gastrointestinal side effects and improving pharmacokinetic profiles by minimizing exposure to hydrolysis and optimizing absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If fumaric acid esters are released rapidly in the gastrointestinal tract, then therapeutic effect is achieved quickly, but gastrointestinal side effects increase and treatment duration is shortened
Solution Approach 1:
The patent segments the release process into multiple phases using an erosion matrix with rate-controlling agents. The matrix erodes gradually in stages, controlling the release of fumaric acid esters to avoid sudden high concentrations that cause GI side effects, while still achieving therapeutic levels over time.
Solution Approach 2:
The erosion matrix acts as an intermediary between the fumaric acid esters and the gastrointestinal tract. It mediates the release process by controlling erosion rate, preventing direct contact of high drug concentrations with the GI mucosa, thereby reducing side effects while maintaining therapeutic efficacy.
2Speed
If fumaric acid esters are released quickly, then initial therapeutic effect is achieved, but treatment duration is insufficient and recurrence rate remains high
Solution Approach 1:
The erosion matrix provides continuous release of fumaric acid esters over an extended period. As the matrix erodes gradually, it maintains a sustained presence of the active substance in the gastrointestinal tract, ensuring continuous therapeutic action that prevents recurrence and extends treatment duration.
Solution Approach 2:
The release system is dynamic, with the erosion matrix adjusting its degradation rate based on environmental conditions (pH, enzymes). This dynamic erosion process allows the system to adapt release rates to maintain therapeutic levels throughout the treatment period, extending duration of action.
3Object-affected harmful factors
If fumaric acid esters are exposed to alkaline environment in the small intestine, then absorption is enhanced, but hydrolysis and degradation increase
Solution Approach 1:
The erosion matrix is designed to undergo preliminary erosion in the acidic stomach environment before the fumaric acid esters are fully exposed to the alkaline small intestine. This preliminary action protects the esters from immediate hydrolysis in the alkaline environment while still allowing gradual release and absorption to occur.
Solution Approach 2:
The matrix composition parameters are optimized to change erosion rate based on pH conditions. In acidic environments, erosion is slower, protecting the esters. In alkaline environments, controlled erosion continues at a rate that balances absorption enhancement with minimized hydrolysis loss.
4Object-affected harmful factors
If enteric coating is applied to protect from gastric acid, then gastrointestinal side effects are reduced, but manufacturing complexity and coating requirements increase
Solution Approach 1:
The patent merges the enteric coating function with the erosion matrix structure. The rate-controlling agents in the matrix provide both erosion control and pH-dependent release characteristics, combining protective and release functions into a single integrated system, thereby reducing overall formulation complexity.
Solution Approach 2:
The erosion matrix serves multiple functions simultaneously: it acts as a protective barrier against gastric acid, controls release rate, and provides sustained delivery. This multi-functionality eliminates the need for separate enteric coating layers, simplifying the overall formulation while achieving the desired protective effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides reduced gastrointestinal side effects, improved treatment efficacy, and enhanced bioavailability with a more stable and prolonged release of fumaric acid esters, leading to better patient compliance and tolerability compared to existing treatments.
Implementation Method 1
erosion of said erosion matrix permits controlled or sustained release of said fumaric acid esters
Implementation Method 2
Fumaric acid esters, such as dimethyl fumarate, can be subject to degradation and hydrolysis
Data Source
Figure 1~2
AI summary
A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).